Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
Globenewswire·2025-11-17 13:45
MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported financial results for the first quarter ended September 30, 2025 (Year end June 30). Corporate and R&D Highlights Advancing PRP Toward Phase 1b First-in-Human Trial (2026) Propanc continues to advance its lead candidate, PRP, toward ...